Biogen News and Research

RSS
Rituxan's sBLA receives a Complete Response from the FDA

Rituxan's sBLA receives a Complete Response from the FDA

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

FBC Acquisition commences tender offer to acquire all outstanding shares of Facet Biotech

FBC Acquisition commences tender offer to acquire all outstanding shares of Facet Biotech

H1N1 infected people continue to shed live virus days after the symptoms

H1N1 infected people continue to shed live virus days after the symptoms

Genentech releases Phase III PRIMA study findings

Genentech releases Phase III PRIMA study findings

GENova to sign extensive collaboration agreement with Beckpharma

GENova to sign extensive collaboration agreement with Beckpharma

Decision Resources forecasts sales of Rituxan/MabThera, Erbitux and Herceptin

Decision Resources forecasts sales of Rituxan/MabThera, Erbitux and Herceptin

Linguistic Systems is MBC's first language translation member

Linguistic Systems is MBC's first language translation member

Genova gains access to Big Pharma's distribution channels

Genova gains access to Big Pharma's distribution channels

Elan rectifies Tysabri Collaboration Agreement breach

Elan rectifies Tysabri Collaboration Agreement breach

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Results further support the benefits of TYSABRI for multiple sclerosis patients

Results further support the benefits of TYSABRI for multiple sclerosis patients

Neurologists recommend oral cladribine for treating multiple sclerosis

Neurologists recommend oral cladribine for treating multiple sclerosis

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

North Carolina Biotechnology Center awarded a transformational grant by the Biogen Idec Foundation

North Carolina Biotechnology Center awarded a transformational grant by the Biogen Idec Foundation

Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

Biogen Idec offers to completely acquire Facet

Biogen Idec offers to completely acquire Facet

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

Aaron Whiteman to be the new CEO of GENova Biotherapeutics